Sector Update: Healthcare Stocks Flat to Higher Premarket Friday

MT newswire2026/09/11 13:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

09:16 AM EDT, 09/11/2026 (MT Newswires) -- Healthcare stocks were flat to higher premarket Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.8%. Exelixis (EXEL) stock was down more than 3%after the company said the US Food and Drug Administration extended the review period for its new drug application for its metastatic colorectal cancer candidate zanzalintinib, in combination with atezolizumab, by three months. Edwards Lifesciences (EW) maintained its 2026 financial outlook after US health regulators released an updated national coverage decision for transcatheter aortic valve replacement. Shares of Edwards Lifesciences were up 1% pre-bell. Nutex Health (NUTX) said an unauthorized third party has published data allegedly obtained during a previously disclosed cybersecurity incident. Nutex Health shares were 0.4% higher premarket.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

BUZZ-3M India shares fall to 19-month low due to quarterly profit decline

路透社•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53